Your browser doesn't support javascript.
X-Linked Inhibitor of Apoptosis (XIAP) deficiency presenting as hemophagocytic lymphohistiocytosis triggered by drug allergy
Clinical Immunology Communications ; 3:46-50, 2023.
Article in English | EMBASE | ID: covidwho-2266269
ABSTRACT
X-linked inhibitor of apoptosis (XIAP) deficiency is a primary immunodeficiency associated with recurrent hemophagocytic lymphohistiocytosis (HLH) episodes. The clinical phenotypes of XIAP deficiency vary, ranging from splenomegaly to life-threatening inflammation. We report a case of XIAP deficiency with unusual late-onset HLH presentation likely triggered by a drug allergy. A previously healthy adolescent boy presented to the hospital with fever and rash seven days after starting antibiotics for a neck abscess. Laboratory evaluation demonstrated cytopenias, elevated liver enzymes, and increased inflammatory markers. Initially, antibiotics were discontinued due to concern for drug rash. He continued to deteriorate clinically and became hypotensive. Additional testing revealed decreased NK cell function, as well as elevated ferritin, triglycerides, and soluble IL-2 receptor. SLAM-Associated Protein (SAP) and XIAP evaluation by flow cytometry demonstrated decreased XIAP expression. Subsequently, genetic testing revealed a known pathogenic mutation in BIRC4 (c.421_422del), confirming the diagnosis of XIAP deficiency.Copyright © 2023
Keywords
birc4, Drug allergy, Hemophagocytic lymphohistiocytosis, X-linked lymphoproliferative disorder, XIAP deficiency, abdominal pain, abscess/dt [Drug Therapy], abscess/su [Surgery], abscess drainage, adolescent, article, body temperature measurement, case report, cell function, clinical article, clinical examination, coronavirus disease 2019/dt [Drug Therapy], cytopenia/di [Diagnosis], disease course, drug eruption/si [Side Effect], drug hypersensitivity, drug safety, drug withdrawal, emergency ward, ferritin blood level, fever/di [Diagnosis], flow cytometry, gene mutation, genetic screening, head and neck infection/co [Complication], head and neck infection/dt [Drug Therapy], hemophagocytic syndrome/di [Diagnosis], hemophagocytic syndrome/dt [Drug Therapy], hospital admission, hospital discharge, human, human cell, hypertransaminasemia/di [Diagnosis], hypotension, immune deficiency/di [Diagnosis], immune deficiency/dt [Drug Therapy], laboratory test, leukopenia/di [Diagnosis], lymphadenitis/di [Diagnosis], lymphadenitis/dt [Drug Therapy], maculopapular rash/di [Diagnosis], male, natural killer cell, neck swelling, pediatric intensive care unit, protein blood level, protein expression, rash, secondary infection/di [Diagnosis], secondary infection/dt [Drug Therapy], sepsis/dt [Drug Therapy], therapy effect, thrombocytopenia/di [Diagnosis], treatment duration, treatment withdrawal, triacylglycerol blood level, vomiting, casirivimab plus imdevimab/dt [Drug Therapy], casirivimab plus imdevimab/pv [Special Situation for Pharmacovigilance], cefalexin/ae [Adverse Drug Reaction], cefalexin/dt [Drug Therapy], cefalexin/po [Oral Drug Administration], cefalexin/pv [Special Situation for Pharmacovigilance], cefalexin/tm [Unexpected Outcome of Drug Treatment], cotrimoxazole/ae [Adverse Drug Reaction], cotrimoxazole/dt [Drug Therapy], cotrimoxazole/po [Oral Drug Administration], cotrimoxazole/pv [Special Situation for Pharmacovigilance], dexamethasone/dt [Drug Therapy], dexamethasone/iv [Intravenous Drug Administration], dexamethasone/pv [Special Situation for Pharmacovigilance], ferritin/ec [Endogenous Compound], interleukin 2 receptor/ec [Endogenous Compound], meropenem/dt [Drug Therapy], meropenem/pv [Special Situation for Pharmacovigilance], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], prednisone/pv [Special Situation for Pharmacovigilance], signaling lymphocyte activation molecule associated protein/ec [Endogenous Compound], triacylglycerol/ec [Endogenous Compound], X linked inhibitor of apoptosis/ec [Endogenous Compound], BIRC4 gene, neck abscess/dt [Drug Therapy], neck abscess/su [Surgery], X linked inhibitor of apoptosis deficiency/di [Diagnosis], X linked inhibitor of apoptosis deficiency/dt [Drug Therapy]

Full text: Available Collection: Databases of international organizations Database: EMBASE Language: English Journal: Clinical Immunology Communications Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Language: English Journal: Clinical Immunology Communications Year: 2023 Document Type: Article